trending Market Intelligence /marketintelligence/en/news-insights/trending/Ln9DErqFdxoSKCHWp6Zhxg2 content esgSubNav
In This List

Abattis Bioceuticals to acquire Green Tree Therapeutics

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


Abattis Bioceuticals to acquire Green Tree Therapeutics

Medical cannabis company Abattis Bioceuticals Corp. is looking to acquire Green Tree Therapeutics, which sells vaporizers across North America.

The company has entered a nonbinding agreement to buy Winston Resources Inc., which owns Green Tree Therapeutics.

Abattis plans to issue 5.5 million of its shares to Green Tree shareholders and another 25 million shares to Winston Resources as consideration for the purchase.

The Green Tree Therapeutics buy will help provide Abattis with an entry point into the vaporizers market, the company's CEO, Rob Abenante, said in a statement.